RFK pick poses uncertainty in areas of healthcare sector, says Wolfe Research's Marcus Tobin
Tobin Marcus, Wolfe Research policy and politics head, joins CNBC's 'Squawk Box' to discuss what Trump's pick for HHS ...
Fintel on MSN2d
Wolfe Research Downgrades Matson (MATX)
Fintel reports that on November 18, 2024, Wolfe Research downgraded their outlook for Matson (NYSE:MATX) from Outperform to ...
Business Wire14h
Hess to Participate in Wolfe Research Oil & Gas Conference
NEW YORK-- ( BUSINESS WIRE )--Hess Corporation (NYSE: HES) announced today that John Hess, Chief Executive Officer, will ...
bovnews19h
Wolfe Research Just Upgraded TransUnion (TRU) Stock—What Does This Mean for Investors?
On Monday, TransUnion (TRU) stock saw a modest uptick, ending the day at $96.93 which represents a slight increase of $1.27 or 1.33% from the prior close of $95.66. The stock opened at $95.91 and ...
Matson downgraded to Peer Perform from Outperform at Wolfe Research
Wolfe Research downgraded Matson (MATX) to Peer Perform from Outperform. The firm cites valuation for the downgrade. Matson has materially ...
Wolfe Research starts Regeneron at Outperform, sees ‘attractive entry point’
Wolfe Research initiated coverage of Regeneron (REGN) with an Outperform rating and $1,150 price target Eylea patent litigation concerns had ...
bovnews1d
Why Did Wolfe Research Give Gilead Sciences, Inc. (GILD) Stock Outperform Rating?
On Friday, Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $88.4 which represents a decrease of $-3.71 or -4.03% from the prior close of $92.11. The stock opened at $91.71 and ...
Amgen (NASDAQ:AMGN) Research Coverage Started at Wolfe Research
Wolfe Research started coverage on shares of Amgen (NASDAQ:AMGN – Free Report) in a report published on Friday, MarketBeat reports. The brokerage issued a peer perform rating on the medical research ...
Investing5d
Wolfe Research sets stock target on Veracyte, cites growth potential
On Friday, Wolfe Research initiated coverage on shares of Veracyte, Inc (NASDAQ:VCYT), a diagnostics company, with an Outperform rating and a price target of $50.00. The firm highlighted Veracyte ...
Nasdaq5d
Wolfe Research starts BioMarin at Outperform given its blockbuster with Voxzogo
Wolfe Research initiated coverage of BioMarin (BMRN) with an Outperform rating and $95 price target With limited downside risk following recent share pullback, a new management team, and robust ...
Seeking Alpha4d
U.S. Pharma is largely immune from 'MAHA' impact: Wolfe
Wolfe Research argues that despite a near-term impact, large-cap U.S. pharma stocks are largely immune from the anti-chronic disease movement "Make America Healthy Again," championed by Robert F.
Nasdaq5d
Wolfe Research Initiates Coverage of AbbVie (SNSE:ABBVCL) with Outperform Recommendation
Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of AbbVie (SNSE:ABBVCL) with a Outperform recommendation. What is the Fund Sentiment? There are 4,922 funds or ...